Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach.
Looking for a particular Ocugen employee's phone or email?
The Ocugen annual revenue was $28.4 million in 2026.
Shankar Musunuri is the Chairman, CEO and Co-Founder of Ocugen.
98 people are employed at Ocugen.
Ocugen is based in Malvern, Pennsylvania.
The NAICS codes for Ocugen are [32, 32541, 3254, 325].
The SIC codes for Ocugen are [283, 28].